Erythropoietin (Epo) is a true hematopoietic hormone produced in response to lowered oxygen tension. The liver is the main source of Epo during most of fetallife, but the liver to kidney switch occurs around birth so that 90% of Epo synthesis takes place in the kidney very soon in life. E!evated serum Epo levels are observed at birth in the case of maternaI hypertension, akoholism, or diabetes ...

The pharmacokinetic profile of recombinant human erythropoietin (rHuEpo) was studied after a single intravenous dose of 150 U/kg in ten patients with various degrees of renal function: group I, creatinine clearance greater than 80 ml/min, n = 2; group II, creatinine clearance 10-50 ml/min, n = 6; group III, creatinine clearance less than 3 ml/min (patients undergoing haemodialysis) n = 2. Eryth...

Anemia is one of the most serious complications in patients on dialysis. Erythropoietin improves the anemia. However, erythropoietin resistance is sometimes encountered from causes such as functional iron deficiency, secondary hyperparathyroidism, blood loss, or interaction with other drugs. To clarify the interaction between erythropoietin and the renin-angiotensin system, we studied the maint...

BACKGROUND Recombinant human erythropoietin (rHuEPO) treatment can increase hemoglobin levels and decrease transfusion requirements. This study aims to investigate how blood transfusion influences Hemoglobin levels in patients receiving rHuEPO for 12 weeks. MATERIALS AND METHODS This was a case-control study of 60 patients less than 15 years with anemia and a solid tumor in any location betwe...

OBJECTIVE The efficacy and safety of recombinant human erythropoietin (rHuEPO) treatment in chemotherapy-induced anemia in children were investigated. rHuEPO is used to treat chemotherapy-induced anemia. Several studies recommend 150 to 300 IU/kg rHuEPO for 2 to 8 months. There are only a few controlled trials in children and no precise data about the optimal dose and duration of rHuEPO treatme...

BACKGROUND AND OBJECTIVES We previously developed blood tests that were introduced at the Sydney 2000 Olympic Games to identify athletes injecting recombinant human erythropoietin (rHuEPO). The aim of this study was to re-analyse our existing database to develop models with heightened sensitivity, using wherever possible blood parameters measurable with appropriate standards of analytical perfo...

BACKGROUND Human recombinant erythropoietin (rHuEpo) that is used for the treatment of the chemotherapy-induced anaemia in cancer patients was shown to cause detrimental effects on the course of disease due to increased adverse events inflicting patient's survival, potentially related to rHuEpo-induced cancer progression. In this study, we elucidate the effect of rHuEpo administration on breast...

Human recombinant erythropoietin is a synthetic hormone for treatment of some kinds of anemia. In this study, the effect of this hormone was investigated on blood cell changes in adult and immature rats. For this purpose, the hormone was administered at doses of 50, 100, and 200 IU/Kg (s.c.) twice a week for a period of 6 weeks. Then, the number of red blood cells (RBC), subtypes of white blood...

UNLABELLED Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in the FXN gene leading to reduced expression of the mitochondrial protein frataxin. Recombinant human erythropoietin (rhuEPO) is suggested to increase frataxin levels, alter mitochondrial function and improve clinical scores in FRDA patients. Aim of the present pilot study was to investigate mitochondrial metabolism of ske...